Helmut Jeggle
Managing Partner at SALVIA GmbH
Munich, Bavaria
Helmut Jeggle, Managing Partner at SALVIA GmbH is an active investor based in Munich, Bavaria. This profile covers what Helmut Jeggle backs, at which stage, and how founders can reach out in 2026.
Mr. Helmut Jeggle serves as a Board Member at Glycotope. He is a Co-Founder and serves as Board Member at Bambusa Therapeutics. He serves as Deputy Chairman at CorTec. He served as Managing Director at Santo Venture Capital. He served as a Board Member at Ganymed Pharmaceuticals and IQM. He is an accomplished senior executive manager with more than 20 years of international experience in the financial field, including strategic management within corporate/non-corporate environments as well as substantial transactional experience. He is currently the Chief Executive Officer of Salvia GmbH (since 2014). Until 2021, he held CEO positions at Neula Holding GmbH (2010-2021) and AT-Gruppe (2008-2021) and was a manager of Santo Group (2011-2021). He is a member of numerous supervisory boards, including 4SC AG, AiCuris AG, BioNTech SE, and Tonies SE. He holds a degree in business administration from the University of Applied Sciences Neu-Ulm and earned his MBA from the Stuttgart Institute of Management and Technology. He serves as a Board Member at OQmented and November - Vorsorge & Bestattungen. He is the Founder and serves as the Managing Partner at Salvia. He serves as a Board Member at AiCuris. He serves as Managing Director at ATHOS Service. He serves as a Member of the Supervisory Board at BioNTech. He is responsible for the life science initiatives of the Strüngmann brothers. Previously, he was the Head of Business Planning & Analyses at Hexal AG and is currently a member of numerous Supervisory Boards. Hexal was sold to Novartis in 2005 for $8.3bn in cash. He has a degree in business administration from the FH Neu-Ulm and earned his MBA from the Stuttgart Institute of Management and Technology (SIMT) during his time at Hexal.
- Investor type
- AngelVCPE
- Stages
- Early Stage VentureSeries ASeries B
- Invests in
- Healthcare & BiotechQuantum & SemiconductorsBiotech & Pharma
- Location
- Munich, Bavaria
- Typical check
- $1M
- Past investments
- 5
Notable investments
IQM Quantum ComputersBioNTech SE
4SC AGAiCuris Anti-infective Cures AGHow to reach Helmut Jeggle
Angels and operators like Helmut Jeggle reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Reach active investors like this one
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "Helmut Jeggle." Round Funded investor database, updated September 9, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/investor/helmut-jeggle-231593-6
Frequently Asked Questions
What does Helmut Jeggle invest in?
Helmut Jeggle invests in Healthcare & Biotech, Quantum & Semiconductors and Biotech & Pharma, typically at Early Stage Venture, Series A and Series B. Match your sector and stage, then reach out with a personalized pitch.
What stage does Helmut Jeggle invest at?
Helmut Jeggle typically invests at Early Stage Venture, Series A and Series B. Lead with traction that fits the stage when you reach out.
What is Helmut Jeggle's typical check size?
Helmut Jeggle typically writes checks around $1M. Use it as a signal for whether your raise fits their stage.
How do founders reach investors like this?
Round Funded lists active investors with verified, professional contact details for signed-up founders. Filter by sector, stage and location, then send a personalized pitch from your own inbox.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.